wow, very interesting!
Characteristics of patients who have had positive results from CCSVI treatment indicate that most beneficial groups are:
Relapsing-Remitting type of MS
At young age
With short disease duration
With lower baseline EDSS.
Young age is defined as under 30; short disease duration is defined as 5 years or less.
Even if these are trends, there are still PP patients in the improvement category and RR patients in the nonimprovement category, etc.
This is measuring improvement as an improvement in EDSS, which does not capture all possible improvements such as in vision, fatigue, etc.
It is quite possible that PP patients have more complicated azygous disease (see the recent discussion in DSASQ, of renal veins and azygous stenoses not seen on venogram but found with IVUS). So, fewer improvements for PP patients could be a result of insufficient treatment of the complicated azygous.
I would take these as preliminary trends but would want to see the technique perfected (or as close as possible) before taking them too much to heart.